TAP1 and breast carcinoma: To address this issue, we used triplicate breast cancer specimens from 160 female patients, analyzed in a parallel fashion by using tissue microarrays (TMAs) [24–26], to determine whether TAP1 and TAP2 were downregulated in specific subsets of breast cancer or were associated with other clinicopathologic features of tumors.